Shattuck Labs, Inc. (STTK)Healthcare | Biotechnology | Austin, United States | NasdaqGS
7.53 USD
+0.18
(2.449%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.64 +0.11 (1.461%) ⇧ (April 17, 2026, 6:19 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 7:22 p.m. EDT
Shattuck Labs is a textbook momentum trap masquerading as a breakthrough biotech story. While the stock has surged over 50% on clinical optimism and analyst upgrades, the fundamentals tell a grim story: negative margins, massive burn rates, and a P/S ratio of nearly 570x. The lack of options open interest is a massive red flag, indicating that smart money is not backing this rally with actual capital allocation, leaving retail investors holding the bag. The forecast model's high heteroscedasticity confirms the price action is unstable and unpredictable, making this a high-risk momentum play with a weak long-term foundation. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.269726 |
| AutoARIMA | 0.269727 |
| AutoTheta | 0.273011 |
| MSTL | 0.279737 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 136.36 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.071 |
| Excess Kurtosis | -1.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.938 |
| Revenue per Share | 0.014 |
| Market Cap | 569,130,880 |
| Forward P/E | -15.77 |
| Beta | 1.29 |
| Website | https://www.shattucklabs.com |
As of April 18, 2026, 7:22 p.m. EDT: Options flow is currently negligible with zero open interest across all expirations and strikes. Activity is restricted to single lots of volume at the current price ($7.50) and deep OTM puts ($5.00) for longer dates, suggesting a lack of institutional positioning or hedging. Speculators are currently not betting on a directional move, likely due to the recent massive volatility; the data shows no conviction in either calls or puts, creating a 'wait-and-see' environment despite the price surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 8.592357 |
| Address1 | 500 West 5th Street |
| Address2 | Suite 1200 |
| All Time High | 60.516 |
| All Time Low | 0.692 |
| Ask | 9.22 |
| Ask Size | 2 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 433,230 |
| Average Daily Volume3 Month | 615,767 |
| Average Volume | 615,767 |
| Average Volume10Days | 433,230 |
| Beta | 1.294 |
| Bid | 5.46 |
| Bid Size | 2 |
| Book Value | 1.302 |
| City | Austin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.53 |
| Current Ratio | 11.695 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.67 |
| Day Low | 7.16 |
| Debt To Equity | 2.938 |
| Display Name | Shattuck Labs |
| Earnings Timestamp | 1,772,717,400 |
| Earnings Timestamp End | 1,777,552,200 |
| Earnings Timestamp Start | 1,777,552,200 |
| Ebitda | -47,739,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -9.703 |
| Enterprise To Revenue | 463.235 |
| Enterprise Value | 463,234,560 |
| Eps Current Year | -0.51645 |
| Eps Forward | -0.47752 |
| Eps Trailing Twelve Months | -0.7 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.494 |
| Fifty Day Average Change | 2.0360003 |
| Fifty Day Average Change Percent | 0.37058616 |
| Fifty Two Week Change Percent | 859.23566 |
| Fifty Two Week High | 7.68 |
| Fifty Two Week High Change | -0.14999962 |
| Fifty Two Week High Change Percent | -0.019531202 |
| Fifty Two Week Low | 0.712 |
| Fifty Two Week Low Change | 6.8180003 |
| Fifty Two Week Low Change Percent | 9.575843 |
| Fifty Two Week Range | 0.712 - 7.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,602,250,200,000 |
| Float Shares | 47,568,019 |
| Forward Eps | -0.47752 |
| Forward P E | -15.768974 |
| Free Cashflow | -21,513,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -1.9510001 |
| Gross Profits | -1,951,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.050869998 |
| Held Percent Institutions | 0.63732 |
| Implied Shares Outstanding | 75,581,787 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-10-09 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas. |
| Long Name | Shattuck Labs, Inc. |
| Market | us_market |
| Market Cap | 569,130,880 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_378179277 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -48,809,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 569,130,856 |
| Number Of Analyst Opinions | 6 |
| Open | 7.45 |
| Operating Cashflow | -39,882,000 |
| Operating Margins | -51.427002 |
| Payout Ratio | 0.0 |
| Phone | 512 900 4690 |
| Post Market Change | 0.10999966 |
| Post Market Change Percent | 1.4608188 |
| Post Market Price | 7.64 |
| Post Market Time | 1,776,464,357 |
| Previous Close | 7.35 |
| Price Eps Current Year | -14.580309 |
| Price Hint | 2 |
| Price To Book | 5.78341 |
| Price To Sales Trailing12 Months | 569.13086 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.07 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | 0.18 |
| Regular Market Change Percent | 2.44898 |
| Regular Market Day High | 7.67 |
| Regular Market Day Low | 7.16 |
| Regular Market Day Range | 7.16 - 7.67 |
| Regular Market Open | 7.45 |
| Regular Market Previous Close | 7.35 |
| Regular Market Price | 7.53 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 302,178 |
| Return On Assets | -0.35306 |
| Return On Equity | -0.60252 |
| Revenue Per Share | 0.014 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 75,581,787 |
| Shares Percent Shares Out | 0.0194 |
| Shares Short | 1,466,321 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,604,787 |
| Short Name | Shattuck Labs, Inc. |
| Short Percent Of Float | 0.020399999 |
| Short Ratio | 1.89 |
| Source Interval | 15 |
| State | TX |
| Symbol | STTK |
| Target High Price | 15.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 9.0 |
| Total Cash | 78,065,000 |
| Total Cash Per Share | 1.091 |
| Total Debt | 2,421,000 |
| Total Revenue | 1,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.7 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.01338 |
| Two Hundred Day Average Change | 4.51662 |
| Two Hundred Day Average Change Percent | 1.4988551 |
| Type Disp | Equity |
| Volume | 302,178 |
| Website | https://www.shattucklabs.com |
| Zip | 78,701 |